博瑞医药：股价腰斩股东减持 公司拟回购不超2000万元

Group 1 - The core point of the news is that Borui Pharmaceutical (688166.SH) is facing significant stock price pressure, leading to a share reduction by a major shareholder and a subsequent share buyback announcement [1][2] - As of September 26, 2025, the shareholder Advanced Manufacturing Industry Investment Fund reduced its holdings by 5.301792 million shares, accounting for 1.25% of the total share capital, with a total value of approximately 440 million yuan [1] - The company's stock price has dropped nearly 50% from its peak of 122.59 yuan on August 6, 2025, to a closing price of 59.44 yuan on September 29, 2025 [1] Group 2 - In the first half of 2025, the company reported operating revenue of 537 million yuan, a year-on-year decline of 18.28% [2] - The net profit attributable to shareholders was only 17.1732 million yuan, down 83.85% year-on-year, primarily due to decreased demand and pricing for its key product, Oseltamivir, amid changing flu trends and intensified market competition [2] - The decline in net profit was also influenced by high base effects from last year's temporary demand for high-margin antifungal raw materials, as well as increased depreciation costs from the conversion of construction in progress [2]